SCHEMBL6030618

SCHEMBL6030618

CCCCCCCCOC(=O)Nc1scc(CCCCCC)c1C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 2/20 0.45
CSNK2A1 P68400 2/20 0.45
ALDH1A1 P00352 1/20 0.43
GPR35 Q9HC97 1/20 0.43
EPHX1 P07099 1/20 0.43
PPARA Q07869 3/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
BID P55957 3/20 0.42
MCL1 Q07820 3/20 0.42
BCL2L1 Q07817 2/20 0.42
BAK1 Q16611 2/20 0.42
KAT8 Q9H7Z6 2/20 0.42
PPARG P37231 2/20 0.42
EP300 Q09472 1/20 0.42
KAT2A Q92830 1/20 0.42
KAT2B Q92831 1/20 0.42
KAT5 Q92993 1/20 0.42
SAE1 Q9UBE0 1/20 0.42
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6030373 0.86 CSNK2A2 (0.46) CSNK2A2CSNK2A1ALDH1A1EPHX1L3MBTL1
SCHEMBL6029667 0.85 ALDH1A1 (0.40) CSNK2A2CSNK2A1ALDH1A1EPHX1L3MBTL1
SCHEMBL6206821 0.81 MEN1 (0.52) ALDH1A1EPHX1L3MBTL1PPARGNPC1
SCHEMBL6031361 0.80 CSNK2A2 (0.41) CSNK2A2CSNK2A1ALDH1A1EPHX1L3MBTL1
SCHEMBL6030589 0.78 TSHR (0.47) ALDH1A1EPHX1L3MBTL1NPC1RAB9A
SCHEMBL6031543 0.77 ALDH1A1 (0.45) CSNK2A2CSNK2A1ALDH1A1EPHX1NPC1
SCHEMBL6029929 0.77 ALDH1A1 (0.45) CSNK2A2CSNK2A1ALDH1A1EPHX1NPC1
SCHEMBL10489793 0.77 BID (0.56) PPARABIDMCL1BCL2L1BAK1
SCHEMBL6031306 0.75 HSD17B10 (0.54) CSNK2A2CSNK2A1ALDH1A1EPHX1NPC1
SCHEMBL6031439 0.75 HSD17B10 (0.54) CSNK2A2CSNK2A1ALDH1A1EPHX1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7064122-B2 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2006-06-20 US disclosed
EP-1467978-A4 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARM INC (US) 2005-11-02 EP disclosed
EP-1467978-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI Pharmaceuticals, Inc. (US) 2004-10-20 EP disclosed
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. 2003-10-16 US disclosed
WO-2003053944-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARMACEUTICALS, INC. (US) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use PNLIP, LIPC, CEL CSNK2A2 1345/4885CSNK2A1 1181/4885ALDH1A1 1832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.